Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy - PubMed (original) (raw)

Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy

J Walker et al. Eur J Cancer. 2004 Mar.

Abstract

Resistance to cancer chemotherapy involves both altered drug activity at the designated target and modified intra-tumour pharmacokinetic properties (e.g. uptake, metabolism). The membrane transporter P-glycoprotein (P-gp) plays a major role in pharmacokinetic resistance by preventing sufficient intracellular accumulation of several anticancer agents. Whilst inhibiting P-gp has great potential to restore chemotherapeutic effectiveness in blood-borne cancers, the situation in solid tumours is less clear. Therefore, the degree of resistance tumours pose to the cytotoxicity of vinblastine and doxorubicin was characterised using the multicellular tumour spheroid model. Tumour spheroids were generated from either drug-sensitive MCF7(WT) breast cancer cells or a resistant P-gp-expressing variant (NCI/ADR(Res)). Drug-induced cytotoxicity in tumour spheroids was measured using an outgrowth assay and compared with that observed in monolayer cultures. As anticipated, the 3-D organisation of MCF7(WT) in tumour spheroids was associated with a reduction in the potency of doxorubicin and vinblastine-i.e. the inherent multicellular resistance phenomenon. In contrast, tumour spheroids from NCI/ADR(Res) cells did not display multicellular resistance. However their constitutive expression of P-gp reduced the potency of both anticancer drugs. Moreover, the highly potent P-gp inhibitor, the anthranilic acid derivative, XR9576, was able to restore the cytotoxic efficacy of both drugs in tumour spheroids comprising NCI/ADR(Res) cells. The results suggest that inhibition of P-gp in solid tumours is achievable and that generation of potent inhibitors will provide a significant benefit towards restoration of chemotherapy in solid tissues.

PubMed Disclaimer

Cited by

Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells.
Janigro D, Perju C, Fazio V, Hallene K, Dini G, Agarwal MK, Cucullo L. Janigro D, et al. BMC Cancer. 2006 Mar 17;6:72. doi: 10.1186/1471-2407-6-72. BMC Cancer. 2006. PMID: 16545134 Free PMC article.
The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.
Sarisozen C, Abouzeid AH, Torchilin VP. Sarisozen C, et al. Eur J Pharm Biopharm. 2014 Oct;88(2):539-50. doi: 10.1016/j.ejpb.2014.07.001. Epub 2014 Jul 10. Eur J Pharm Biopharm. 2014. PMID: 25016976 Free PMC article.
Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art.
Lebastchi AH, Kunstman JW, Carling T. Lebastchi AH, et al. J Oncol. 2012;2012:234726. doi: 10.1155/2012/234726. Epub 2012 Oct 18. J Oncol. 2012. PMID: 23125857 Free PMC article.
Structure-activity relationships of tariquidar analogs as multidrug resistance modulators.
Pajeva IK, Wiese M. Pajeva IK, et al. AAPS J. 2009 Sep;11(3):435-44. doi: 10.1208/s12248-009-9118-z. Epub 2009 Jun 6. AAPS J. 2009. PMID: 19504188 Free PMC article. Review.
A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells.
Ta HQ, Thomas KS, Schrecengost RS, Bouton AH. Ta HQ, et al. Cancer Res. 2008 Nov 1;68(21):8796-804. doi: 10.1158/0008-5472.CAN-08-2426. Cancer Res. 2008. PMID: 18974122 Free PMC article.

Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy - PubMed (original) (raw)